---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-347911"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2026-08-13T11:42:49+00:00"
generated_at: "2026-08-13T11:45:18.875869+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology Q2 net loss $25.3M; $50M private placement extends cash runway into Q2 2027

## Summary
- Net loss $25.3M ($0.40/share) vs $18.4M ($0.30) in Q2 2025; R&D $16.1M, G&A $9.9M.
- Completed July 2, 2026 private placement: ~$50M upfront gross, up to $64M more if warrants exercised.
- Cash, equivalents, restricted cash, and short-term investments $34.5M at June 30, 2026; runway into Q2 2027.
- MICVO Phase 1 monotherapy update in 2L+ R/M HNSCC expected Fall 2026; pembrolizumab combo update Q4 2026.
- Interim CEO Tom Civik cites financing and clinical execution; shares outstanding 83.4M as of Aug 12, 2026.

## SEC filing metadata
- accession: 0001193125-26-347911
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2026-08-13T11:42:49+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000119312526347911/0001193125-26-347911-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000119312526347911/pyxs-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-347911
- JSON: https://secwatch.observer/filing/0001193125-26-347911.json
- Plain text: https://secwatch.observer/filing/0001193125-26-347911.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.